| Brenda Elaine Richardson, PT | |
|
3160 W Britton Rd, Suite C, Oklahoma City, OK 73120-2068 | |
| (405) 751-9595 | |
| (405) 755-4045 |
| Full Name | Brenda Elaine Richardson |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 3160 W Britton Rd, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033139274 | NPI | - | NPPES |
| 1194847988 | Other | OK | GROUP NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT1362 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brenda Elaine Richardson, PT 3160 W Britton Rd, Suite C, Oklahoma City, OK 73120-2039 Ph: (405) 751-9595 | Brenda Elaine Richardson, PT 3160 W Britton Rd, Suite C, Oklahoma City, OK 73120-2068 Ph: (405) 751-9595 |
News Archive
The researchers, in partnership with the Cancer Council, Australia, studied 12,618 food advertisements from 11 countries and found that 67 per cent endorsed unhealthy food. The research builds on a previous study at Liverpool which revealed that children would consume twice as many calories from snacks after watching food adverts compared to after viewing advertising for toys and games.
Integrated Diagnostics launched officially today with more than $30 million in funding. A pre-eminent team of scientists and investors are behind the company, which was founded by renowned biotechnology innovator Dr. Leroy Hood. Integrated Diagnostics will focus on developing personalized and preventive diagnostics based on breakthroughs using genomic and proteomic technologies to identify organ-specific proteins.
Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.
Omeros Corporation today announced that the U.S. Food and Drug Administration granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
› Verified 5 days ago
Tressie Mccoy, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 700 Ne 13th St, Oklahoma City, OK 73104 Phone: 405-271-8000 | |
Prof. Martha J Ferretti, PT, MPH, FAPTA Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 801 Ne 13th St, Room 237a, Oklahoma City, OK 73104 Phone: 405-271-2434 Fax: 405-271-2432 | |
Jessica R. Swanson, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 9600 Broadway Ext, Oklahoma City, OK 73114 Phone: 405-230-9000 | |
Tyler Hamilton, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1407 N Robinson Ave, Oklahoma City, OK 73103 Phone: 404-232-8000 | |
Don Van Nguyen, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 923 N Robinson Ave, Oklahoma City, OK 73102 Phone: 405-231-5800 | |
Mr. Ronald Leroy Langham Jr., PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3535 Nw 58th St, Suite 850, Oklahoma City, OK 73112 Phone: 405-602-3295 | |
Hansa Atwal, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 8809 S Sooner Rd Ste E, Oklahoma City, OK 73135 Phone: 405-455-7860 Fax: 405-455-7865 |